文献速递神经肿瘤

T2-FLAIR错配征作为非强化IDH突变型、1p/19q完整低级别胶质瘤影像标志物的验证研究

The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
PubMed 文献 · Neuro Oncol · 2018-01-01

该验证研究评估T2-FLAIR错配征在非强化IDH突变型、1p/19q非共缺失低级别胶质瘤中的可重复性,由2名独立评估者对3个数据库共154例基因分型LGG的MR扫描进行判读。结果显示错配征评估者间一致性为κ=0.75(0.64-0.87),阳性预测值100%、阴性预测值68%、灵敏度51%、特异度100%。

要点

  • T2-FLAIR错配征在非强化LGG中识别IDH突变型星形细胞瘤的阳性预测值为100%、特异度为100%。
  • 错配征评估者间一致性为κ=0.75(0.64-0.87),T2均匀性一致性仅为κ=0.38(0.25-0.52)。
  • 错配征灵敏度为51%、阴性预测值为68%,该非侵入性标志物可能有助于患者咨询和治疗决策。

核心结论

  • 在非强化低级别胶质瘤中,T2-FLAIR错配征是具有稳健评估者间一致性的高度特异影像标志物,用于识别IDH突变型星形细胞瘤。
  • 该非侵入性标志物可能有助于更充分的患者咨询,并可在相当比例的非强化、LGG样病变患者的治疗决策过程中提供帮助。

研究设计与样本

  • 验证研究,评估既往描述的T2-FLAIR错配征的可重复性。
  • 纳入3个独立数据库中已行基因分型的低级别胶质瘤MR扫描共154例(n=154),涵盖弥漫性星形细胞瘤和间变性星形细胞瘤。
  • 由2名独立评估者评估T2-FLAIR错配征的有无及T2加权像上均匀信号的有无,计算Cohen's kappa(κ)评估者间一致性及诊断试验性能。

主要发现

  • T2-FLAIR错配征的评估者间一致性为κ=0.75(0.64-0.87),T2均匀性的一致性为κ=0.38(0.25-0.52)。
  • T2-FLAIR错配征见于38例(25%),阳性预测值为100%,阴性预测值为68%,灵敏度为51%,特异度为100%。

临床怎么用

  • 在非强化低级别胶质瘤中,T2-FLAIR错配征可作为识别IDH突变型星形细胞瘤的高度特异影像标志物,作者认为该标志物可能有助于患者咨询和治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to assess the reproducibility of the previously described T2-fluid attenuated inversion recovery (FLAIR) mismatch sign as a specific imaging marker in non-enhancing isocitrate dehydrogenase (IDH) mutant, 1p/19q non-codeleted lower-grade glioma (LGG), encompassing both diffuse and anaplastic astrocytoma. METHODS: MR scans (n = 154) from 3 separate databases with genotyped LGG were evaluated by 2 independent reviewers to assess (i) presence/absence of "T2-FLAIR mismatch" sign and (ii) presence/absence of homogeneous signal on T2-weighted images. Interrater agreement with Cohen's kappa (κ) was calculated, as well as diagnostic test performance of the T2-FLAIR mismatch sign to identify IDH-mutant astrocytoma. RESULTS: There was substantial interrater agreement for the T2-FLAIR mismatch sign [κ = 0.75 (0.64-0.87)], but only fair agreement for T2 homogeneity [κ = 0.38 (0.25-0.52)]. The T2-FLAIR mismatch sign was present in 38 cases (25%) and had a positive predictive value of 100%, negative predictive value of 68%, a sensitivity of 51%, and a specificity of 100%. CONCLUSIONS: With a robust interrater agreement, our study confirms that among non-enhancing LGG the T2-FLAIR mismatch sign represents a highly specific imaging marker for IDH-mutant astrocytoma. This non-invasive marker may enable a more informed patient counsel and can aid in the treatment decision processes in a significant proportion of patients presenting with non-enhancing, LGG-like lesions.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 2018. PMID: 29590424. doi:10.1093/neuonc/noy048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。